The study investigates IGM-7354, an IL-15/IL-15Rα fused IgM that targets PD-L1 and activates NK and CD8+ T cells. In vivo efficacy and immune engagement were evaluated.
IGM-7354 successfully engages and expands cytotoxic immune subsets and reduces tumor burden in a HIS mouse model.
Humanized BRGSF-HIS mouse model developed by genOway
Immuno-oncology, PD-L1 targeting, IL-15 immunotherapy, human immune system mouse models
Humanized model, BRGSF-HIS, IL-15 fusion, PD-L1 targeting, IgM
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
